Combination Therapy That Includes Daratumumab Lowers Risk of Multiple Myeloma Progression
February 9th 2018Study results show patients with newly diagnosed multiple myeloma showed a lower risk of disease progression or death with daratumumab added to the standard regimen of bortezomib, melphalan and prednisone, than patients who were treated without daratumumab in their drug combination.
Read More
FDA: Kratom Compounds Contain Opioid Properties
February 7th 2018In newly-released scientific analysis and data, the FDA has indicated strong evidence of the presence of compounds in kratom that strongly bind to opioid receptors, according to a statement released by FDA Commissioner Scott Gottlieb, MD.
Read More